Testing a new weight-loss drug for adults with obesity already on GLP-1 drugs
Tests maridebart cafraglutide in adults with obesity who switch from GLP-1 drugs.
Plain-language title generated from the registry record
Registry title: Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Key facts
- Where
- Ponce, Puerto RicoSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT07575399, who can take part
Where in Puerto Rico
- Puerto Rico Medical Research Inc.Ponce, Puerto RicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amgen
- Trial code
- NCT07575399
- Record updated
- 6 November 2026
- Original description
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.Read full original descriptionShow less
A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
Inclusion: Body Mass Index (BMI) ≥ 25 at screening; Weight loss of ≥ 10% on weekly GLP-1 RA; Stable body weight; Stable dose of GLP-1RA; Stable gastrointestinal (GI) tolerability; Contraception for females; Willingness to follow trial procedures for the duration of the trial.
Exclusion: Previous or planned surgical, endoscopic or device-based treatment for obesity; Previous participation in a Maridebart Cafraglutide trial; Obesity induced by other endocrine disorders (ex: Cushing's syndrome); History of malignancy; Type 1/Type 2 diabetes mellitus (DM); Family or personal history of medullary thyroid cancer.